Ocular Therapeutix reports Q3 results, cash runway and plans NDA submission for AXPAXLI in wet AMD

Ocular Therapeutix reported third‑quarter 2026 revenue of $12.87 million, a decline of 11.5% year‑over‑year, and a non‑GAAP loss of $0.42 per share. The company said it has $530.6 million in cash, enough to fund operations into 2028, and remains on track to file a New Drug Application for its AXPAXLI therapy in wet age‑related macular degeneration in the fourth quarter of 2026, using the 505(b)(2) pathway. Management highlighted late‑stage trial data, including about 70% of subjects being dry at week 36 in the SOL‑R study and FDA agreement to shift the SOL‑R primary endpoint to week 40.

The planned Q4 2026 NDA filing could accelerate market entry if approved, potentially generating revenue beyond 2027 (the company’s cash outlook). Analysts note the cash runway supports continued R&D and commercial preparation.

Sources